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Abstract: Fixed drug eruption (FDE) is characterized by recurrent well-deﬁ  ned lesions in the 
same location each time the responsible drug is taken. We report here a case of multiple FDE 
induced by atenolol in a 48-year-old woman conﬁ  rmed by positive patch test in previously 
affected sites. Beta-blockers-induced FDE are very rare. Only two cases had been reported in 
the literature. To the best of our knowledge, this is the ﬁ  rst case reported of atenolol-induced 
FDE conﬁ  rmed by a positive patch test.
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Introduction
Fixed drug eruption (FDE) is characterized by recurrent well-deﬁ  ned lesions in the 
same location each time the responsible drug is taken. We report here a rare case of 
FDE induced by atenolol, a beta-adrenoreceptor-blocking agent.
Case study
A 48-year-old Tunisian woman was referred to our department for the appearance of 
ﬁ  ve inﬂ  ammatory plaques on both legs. She had been treated for hypertension with 
atenolol (Hypoten®, Al-Hikma Pharmaceuticals, Jordan) 100 mg once a day for six 
weeks. No other medications had been taken and she had not previously received beta-
blocking agents. The lesions had begun three weeks after the onset of atenolol. Physical 
examination revealed ﬁ  ve well-demarcated reddish and round plaques with an itching 
and burning sensation on both legs (Figure 1). One of these lesions showed vesicular 
changes. The diagnosis of multiple FDE was suspected and atenolol was discontinued. 
Skin biopsy, taken from a lesion with no vesicular changes, showed focal necrosis of 
keratinocytes, hydropic degeneration of the basal cells, dermal edema and a perivas-
cular lymphocytic inﬁ  ltrate of the upper dermis. These histopathological ﬁ  ndings were 
consistent with the diagnosis of FDE. Topical desonide (Locatop®) was applied twice a 
day and skin lesions resolved within two weeks with a residual pigmentation. 6 weeks 
after complete resolution, patch testing was carried out according to the International 
Contact Dermatitis Research Group (Jacobs et al 1999) recommendations with 10% 
atenolol in petrolatum on a previously affected site of the right leg (Figure 2) and on 
normal skin of the back. A positive reaction (++) was seen at D2 and D3 on the left 
leg but no reaction was detected on the back. Thus, the diagnosis of atenolol-induced 
FDE was established. There was no relapse during a follow-up period of one year.
Discussion
Several drugs can induce FDE. They mostly include nonsteroidal antiinﬂ  ammatory 
drugs, nonopioid analgesics, sulphonamides, and tetracyclines (Savin 2001).
Topical provocation testing has been reported to be useful and safe for the diagnosis 
of FDE when applied on previously affected sites (Alanko et al 1987; Alanko 1994; 
Lee 1998; Ozkaya-Bayazit et al 1999). Patch testing in FDE is still not standardized 
(Ozkaya 2008). Different patch test methods (open/occlusive) and variations in their Clinical, Cosmetic and Investigational Dermatology 2008:1 38
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Figure 1 Well-demarcated plaque of the right leg with erythema and edema.
Figure 2 Positive patch test with 10% atenolol in petrolatum.Clinical, Cosmetic and Investigational Dermatology 2008:1 39
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evaluation (erythema of more than six hours duration/
erythema and inﬁ  ltration) exist (Ozkaya 2008).
Beta-blockers-induced FDE are very rare (Palungwachira 
and Palungwachira 1999; Zaccaria et al 2006). Only two 
cases have been reported in the literature (Palungwachira 
and Palungwachira 1999; Zaccaria et al 2006). They were 
induced by atenolol (Palungwachira and Palungwachira 
1999) and propranolol (Zaccaria et al 2006). None of them 
was conﬁ  rmed by patch testing or systemic provocation 
(Palungwachira and Palungwachira 1999; Zaccaria et al 
2006). Thus, to the best of our knowledge, we report herein 
the ﬁ  rst case of FDE induced by atenolol and conﬁ  rmed by 
a positive patch test on previously affected sites.
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